ENTPD1 (CD39) and NT5E (CD73) expression in human medulloblastoma: an in silico analysis

Marco Antônio Stefani ^1,2, Elizandra Braganhol ³, Guilherme Tomasi Santos ¹

⁰Federal University of Rio Grande Do Sul, Rua Sarmento Leite, 500 Centro Histórico 90050170, Porto Alegre, RS, Brazil.

Purinergic Signalling +

|

July 8, 2024

View abstract on PubMed

Summary

High expression of CD39 (ENTPD1) and CD73 (NT5E) correlates with poorer survival in pediatric medulloblastoma Group 4. These purinergic enzymes may serve as prognostic markers and therapeutic targets for this specific medulloblastoma subtype.

Area Of Science

Pediatric Oncology
Cancer Molecular Biology
Immunology

Background

Medulloblastoma is the most common pediatric malignant brain tumor.
Molecular classification is crucial for understanding medulloblastoma subtypes.
Purinergic signaling enzymes CD39 (ENTPD1) and CD73 (NT5E) influence the tumor microenvironment.

Purpose Of The Study

To investigate the prognostic significance of ENTPD1 and NT5E gene expression in medulloblastoma.
To evaluate CD39 and CD73 as potential biomarkers and therapeutic targets in different medulloblastoma subgroups.

Main Methods

In silico analysis of transcriptome data from the Cavalli Cohort (n=763).
Kaplan-Meier survival analysis with log-rank statistics.
Stratification of analysis by medulloblastoma molecular subgroups (WNT, SHH, Group 3, Group 4).

Main Results

In non-WNT/non-SHH Group 4, high ENTPD1 and NT5E expression correlated with significantly lower overall survival.
In SHH-activated medulloblastoma, high ENTPD1 predicted lower survival, while high NT5E predicted greater survival.
In Group 3, high ENTPD1 expression was linked to better survival, whereas NT5E showed no significant correlation.

Conclusions

ENTPD1 (CD39) and NT5E (CD73) expression levels have differential prognostic value across medulloblastoma subgroups.
These enzymes represent potential prognostic markers and therapeutic targets, particularly in non-WNT/non-SHH Group 4 medulloblastoma.

Keywords:

CD39 CD73 ENTPD1 In silico Medulloblastoma NT5E